Sarah Anis, MD
Ophthalmology · Providence, RINPI 1225276678
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,029 of the $163,320 with a category attached, or 76.6%. 22 manufacturers reported payments, led by AbbVie at 44.0% of the total. Reporting peaked in 2021 at $33,617 and has fallen 50.5% since, to $16,641 in 2025. Among ophthalmology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 537 payments — averaging $304.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$72K
- Aerie Pharmaceuticals, Inc.$40K
- Alcon$35K
- NEW World Medical,inc.$7K
- Glaukos Corporation$5K
- Bausch & Lomb Americas Inc.$1K
- plus $2K from 16 others
Across 1 payment — averaging $8000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ivantis, Inc$8K
What the payments were for
- Consulting fees$13,4238%
- Speaking & faculty fees$125,02977%
- Travel & lodging$12,2548%
- Food & beverage$12,4418%
- Education$1290%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 242 | $71,852 |
| Aerie Pharmaceuticals, Inc. | 69 | $40,133 |
| Alcon | 82 | $35,470 |
| NEW World Medical,inc. | 32 | $6,899 |
| Glaukos Corporation | 16 | $5,112 |
| Bausch & Lomb Americas Inc. | 12 | $1,358 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $827 |
| Sight Sciences, Inc. | 14 | $348 |
| Kala Pharmaceuticals, Inc. | 14 | $265 |
| Astellas Pharma US Inc | 3 | $193 |
| Thea Pharma Inc. | 8 | $168 |
| Novartis | 4 | $160 |
| Amgen(2 entities) | 7 | $126 |
| ANI Pharmaceuticals, Inc. | 5 | $94 |
| AstraZeneca | 1 | $88 |
| Sun Pharmaceutical Industries Inc. | 4 | $68 |
| Apellis Pharmaceuticals, Inc. | 2 | $54 |
| Akorn Operating Company LLC | 2 | $37 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Vyera Pharmaceuticals, LLC | 1 | $18 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Eyepoint US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$71,529
- DURYSTA$66,540
- Rhopressa$65,717
- SIMBRINZA$18,224
- Kahook Dual Blade$4,247
- Ahmed Glaucoma Valve$4,247
- Clearpath$4,074
- Streamline$4,074
- Via360$2,227
- VYZULTA$1,600
- XEN GLAUCOMA TREATMENT SYSTEM$502
- iDoseTR$353
- Clareon$252
- Streamline Surgical System$173
- OMNI(R) SURGICAL SYSTEM (US)$147
- SION SURGICAL INSTRUMENT$147
- Clareon PanOptix Pro$140
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$131
- iStent infinite Trabecular Micro-Bypass System Model iS3$131
- Izervay$125
How this compares
$163,320 in reported general payments places this provider in the 95th percentile of 69 ophthalmology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 639 | $325,165 |
| RhopressaNetarsudil Mesylate | 606 | $302,543 |
| RocklatanNetarsudil Mesylat/Latanoprost | 270 | $131,544 |
| Alphagan PBrimonidine Tartrate | 222 | $101,245 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 280 | $66,851 |
| Latanoprost | 3,620 | $56,654 |
| Brimonidine Tartrate | 1,549 | $56,064 |
| CombiganBrimonidine Tartrate/Timolol | 95 | $51,578 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 269 | $48,735 |
| Travoprost | 231 | $45,658 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,643 | $39,479 |
| Timolol Maleate | 1,302 | $29,465 |
| VyzultaLatanoprostene Bunod | 59 | $28,462 |
| Prednisolone Acetate | 452 | $23,524 |
| Dorzolamide Hcl | 848 | $23,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis | $71,852 | $496,423976 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $40,133 | $434,087876 claims |
| AlconSimbrinza, Azopt | $35,470 | $88,752324 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Loteprednol Etabonate | $827 | $41,072145 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $1,358 | $28,46259 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 ophthalmology providers in Rhode Island.
Other ophthalmology in Providence
- Jesse RichmanProvidence$30K
- Yoash EnzerProvidence$11K
- David TienProvidence$6K
- Jane CookProvidence$4K
- Christopher NewtonProvidence$3K
- Joseph DucharmeProvidence$3K
- King ToProvidence$2K
- Gaurav GuptaProvidence$2K
- Carolina ChiouProvidence$2K
- Ezra GallerProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.